Recently, we used liver biopsies obtained from a mixed gender cohort of morbid obese patients undergoing bariatric surgery showing decreased hepatic expression of AQP9 in obese subjects with NAFLD (Figure 2) (10). Here, AQP9 is linked to metabolic dysfunction-associated steatotic liver disease.